Summary:
Reduced post-transplant performance status because of infectious complications is still a problem following autologous peripheral blood stem cell transplantation (aPBSCT). In this study, a tandem transplantation scheme for 15 patients with breast cancer including etoposide (1500 mg/m2), ifosfamide (12 g/m2) and carboplatin (1500 mg/m2) as conditioning regimens, followed by aPBSCT, was used to evaluate the potential clinical benefit of the additional retransfusion of low numbers of ex vivo expanded committed myeloid postprogenitor cells (PPCs) (median 408 × 103 CFU-c/kg BW, range 0.93–1995) following the second transplantation. Following a 7+2 days expansion (using recombinant human SCF, IL-1β, IL-3, IL-6 + G-CSF), CFU-c generated from CD34-positive cells from leukapheresis products could be expanded by a median factor of 153 (range 5–434). Flow cytometric analysis and morphology of CFUs have shown a nearly exclusive expansion and differentiation of committed myeloid progenitor cells and a significant reduction of CD34-positive cells. In an intra- and interindividual comparison it could be shown that the retransfusion of committed myeloid postprogenitor cells significantly accelerates myeloid recovery. Although retransfusion of PPCs fails to abrogate severe neutropenia following aPBSCT, it significantly ameliorates infectious complications and shortens the duration of hospital stay.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Reich G, Mapara MY, Reichardt P et al. Infectious complications after high-dose chemotherapy and autologous stem cell transplantation: comparison between patients with lymphoma or multiple myeloma and patients with solid tumors. Bone Marrow Transplant 2001; 27: 525–529.
Offidani M, Corvatta L, Olivieri A et al. Infectious complications after autologous peripheral blood progenitor cell transplantation followed by G-CSF. Bone Marrow Transplant 1999; 24: 1079–1087.
Schmitz N, Linch DC, Dreger P et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347: 353–357.
Ketterer N, Salles G, Raba M et al. High CD34(+) cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood 1998; 91: 3148–3155.
Weaver CH, Hazelton B, Birch R et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961–3969.
Weisdorf DJ, Verfaillie CM, Davies SM et al. Hematopoietic growth factors for graft failure after bone marrow transplantation: a randomized trial of granulocyte-macrophage colony- stimulating factor (GM-CSF) versus sequential GM-CSF plus granulocyte- CSF. Blood 1995; 85: 3452–3456.
Reiffers J, Cailliot C, Dazey B et al. Abrogation of post-myeloablative chemotherapy neutropenia by ex-vivo expanded autologous CD34-positive cells. Lancet 1999; 354: 1092–1093.
Koc ON, Gerson SL, Cooper BW et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000; 18: 307–316.
Possinger K, Wilmanns W . Palliative therapeutic control of tumor progression in patients with metastatic breast cancer. Internist (Berl) 1993; 34: 340–350.
Waller CF, von Lintig F, Daskalakis A, Musahl V, Lange W . Mobilization of peripheral blood progenitor cells in patients with breast cancer: a prospective randomized trial comparing rhG-CSF with the combination of rhG-CSF plus rhEpo after VIP-E chemotherapy. Bone Marrow Transplant 1999; 24: 19–24.
Haylock DN, To LB, Dowse TL et al. Ex vivo expansion and maturation of peripheral blood CD34+ cells into the myeloid lineage. Blood 1992; 80: 1405–1412.
Sutherland HJ, Eaves AC, Eaves CJ . Quantitative assays for human hematopoietic progenitor cells. In: Gee A (ed.). Bone Marrow Processing and Purging: A Practical Guide. CRC Press Inc.: Boca Raton, 1991, pp. 155–171.
Metcalf D . Clonal culture of hematopoietic cells: techniques and applications. Elsevier: Amsterdam, 1984.
Sutherland DR, Anderson L, Keeney M et al. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 1996; 5: 213–226.
Olweus J, Lund Johansen F, Terstappen LW . Expression of cell surface markers during differentiation of CD34+, CD38-/lo fetal and adult bone marrow cells. Immunomethods 1994; 5: 179–188.
Piatier-Tonneau D . CD4 Workshop Panel report. In: Kishimoto T, Kikutani H, von dem Borne AE, Goyert SM, Mason D, Miyasaka M. (eds.). Leukocyte Typing IV. Garland Publishing: New York, London, 1997, pp. 49–54.
Paquette RL, Dergham ST, Karpf E et al. Ex vivo expanded unselected peripheral blood: progenitor cells reduce posttransplantation neutropenia, thrombocytopenia, and anemia in patients with breast cancer. Blood 2000; 96: 2385–2390.
McNiece I, Jones R, Bearman SI et al. Ex vivo expanded peripheral blood progenitor cells provide rapid neutrophil recovery after high-dose chemotherapy in patients with breast cancer. Blood 2000; 96: 3001–3007.
Scheding S, Franke H, Diehl V et al. How many myeloid post-progenitor cells have to be transplanted to completely abrogate neutropenia after peripheral blood progenitor cell transplantation? Results of a computer simulation. Exp Hematol 1999; 27: 956–965.
Acknowledgements
The study was supported by Deutsche Krebshilfe. We thank Mrs Linda Gatsch and Mrs Sylvia Kirchner for excellent technical assistance. We thank Dr Rajshri Jayaraman and Dr Harald Wagner for reading the manuscript and for their helpful comments.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Reichle, A., Zaiss, M., Rothe, G. et al. Autologous tandem transplantation: almost complete reduction of neutropenic fever following the second transplantation by ex vivo expanded autologous myeloid postprogenitor cells. Bone Marrow Transplant 32, 299–305 (2003). https://doi.org/10.1038/sj.bmt.1704126
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1704126
Keywords
This article is cited by
-
Formation of an adherent hematopoietic expansion culture using fucoidan
Annals of Hematology (2011)
-
Optimal ex vivo expansion of neutrophils from PBSC CD34+ cells by a combination of SCF, Flt3-L and G-CSF and its inhibition by further addition of TPO
Journal of Translational Medicine (2007)
-
Multipotent neural precursors express neural and hematopoietic factors, and enhance ex vivo expansion of cord blood CD34+ cells, colony forming units and NOD/SCID-repopulating cells in contact and noncontact cultures
Leukemia (2005)